Back to Interventions

Substance / Medication

Interferon alfa-2a

SNOMED 386914007 UMLS C0021734

Overview

Active Ingredient

interferon alfa-2a

RxNorm CUI

5879

Administration & Protocol

Dosing, route, and treatment protocol

Administration details including route, dosing schedules, preparation instructions, and contraindications are pending physician authorship.

Monitoring & Follow-Up

Biomarkers relevant to this intervention via related conditions

LOINC 718-7

secondary

LOINC 26464-8

secondary

LOINC 777-3

primary

Clinical Trials

190 trials linked to this intervention

190

Total Trials

21

Recruiting

76

With Results

Recent Trials

Long-Term Therapy With Ribavirin for Chronic Hepatitis C

NCT00001854Phase 4Completed50 enrolled

Pegylated Interferon and Ribavirin to Treat Chronic Hepatitis C With and Without Kidney Disease

NCT00028093Phase 4Completed50 enrolled

Evaluation of Argatroban Injection in Pediatric Patients Requiring Anticoagulant Alternatives to Heparin

NCT00039858Phase 4Completed24 enrolled

Study of ONTAK (Denileukin Diftitox) in Cutaneous T-Cell Lymphoma (CTCL) Patients

NCT00050999Phase 4Completed195 enrolled

Study of ONTAK (Denileukin Diftitox) in Previously Treated Cutaneous T-Cell Lymphoma Patients

NCT00051012Phase 4Completed86 enrolled

View all 190 trials on ClinicalTrials.gov

Research Evidence

Published studies and systematic reviews

Sort:

Peginterferon alfa-2a (40 kD) stopping rules in chronic hepatitis B: a systematic review and meta-analysis of individual participant data.

Pavlovic Vedran, Yang Lei, Chan Henry Lik-Yuen et al. · Antivir Ther · 2019

PMID: 30865588Meta-Analysis

Efficacy and safety of pegylated interferon alfa-2a or alfa-2b plus ribavirin for the treatment of chronic hepatitis C in children and adolescents: a systematic review and meta-analysis.

Druyts Eric, Thorlund Kristian, Wu Ping et al. · Clin Infect Dis · 2013

PMID: 23243171Meta-Analysis

Peginterferon alfa-2a is superior to peginterferon alfa-2b in the treatment of naïve patients with hepatitis C virus infection: meta-analysis of randomized controlled trials.

Singal Ashwani K, Jampana Sarat C, Anand Bhupinderjit S · Dig Dis Sci · 2011

PMID: 21643737Meta-Analysis

Predicting sustained virological response and anaemia in chronic hepatitis C patients treated with peginterferon alfa-2a (40KD) plus ribavirin.

Snoeck Eric, Wade Janet R, Duff Frank et al. · Br J Clin Pharmacol · 2006

PMID: 17118125Meta-AnalysisFull text (PMC)

Effect of peginterferon alfa-2a on liver histology in chronic hepatitis C: a meta-analysis of individual patient data.

Cammà Calogero, Di Bona Danilo, Schepis Filippo et al. · Hepatology · 2004

PMID: 14767986Meta-Analysis

[HBsAg loss with Pegylated-interferon alfa-2a in hepatitis B patients with partial response to nucleos(t)-ide analog: new switch study].

Hu P, Shang J, Zhang W H et al. · Zhonghua Gan Zang Bing Za Zhi · 2018

PMID: 30481882RCT

Hepatitis B Surface Antigen Loss with Tenofovir Disoproxil Fumarate Plus Peginterferon Alfa-2a: Week 120 Analysis.

Ahn Sang Hoon, Marcellin Patrick, Ma Xiaoli et al. · Dig Dis Sci · 2018

PMID: 30136045RCTFull text (PMC)

Effect on HBs antigen clearance of addition of pegylated interferon alfa-2a to nucleos(t)ide analogue therapy versus nucleos(t)ide analogue therapy alone in patients with HBe antigen-negative chronic hepatitis B and sustained undetectable plasma hepatitis B virus DNA: a randomised, controlled, open-label trial.

Bourlière Marc, Rabiega Pascaline, Ganne-Carrie Nathalie et al. · Lancet Gastroenterol Hepatol · 2017

PMID: 28404133RCT

Predictors of response to tenofovir disoproxil fumarate plus peginterferon alfa-2a combination therapy for chronic hepatitis B.

Marcellin P, Ahn S H, Chuang W-L et al. · Aliment Pharmacol Ther · 2016

PMID: 27629859RCT

CONSORT: Effects of adding adefovirdipivoxil to peginterferon alfa-2a at different time points on HBeAg-positivepatients: A prospective, randomized study.

Zhang Ka, Cao Hong, Liang Jiayi et al. · Medicine (Baltimore) · 2016

PMID: 27495085RCTFull text (PMC)

Research data from MEDLINE/PubMed

Benefits & Expected Outcomes

Benefits, expected outcomes, efficacy data, and NNT (Number Needed to Treat) are pending physician authorship and evidence review.

Risks & Side Effects

Risk profile, common and serious adverse effects, contraindications, and drug interactions are pending physician authorship.

Related Symptoms

Symptoms associated with conditions this intervention addresses

No related symptoms have been mapped yet. Symptom linkages are derived through associated conditions.

Alternatives & Comparisons

Alternative treatments, comparison data, and clinical decision support are pending physician authorship.

Medical Disclaimer

This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider regarding any medical condition or treatment plan.

Do not start, stop, or change any treatment without consulting your healthcare provider.

Specialists

Providers who commonly manage this intervention

Internal Medicine Physician

Internal Medicine

NUCC 207R00000X

Hematology (Internal Medicine) Physician

Internal Medicine — Hematology

NUCC 207RH0000X

Find a Provider

Health Goals

Goals connected through associated conditions

Optimize Iron and Blood Health

Quick Facts

Type: Substance / Medication
Fully Specified Name: Interferon alfa-2a (substance)
SNOMED CT: 386914007
UMLS CUI: C0021734
RxNorm CUI: 5879

Clinical Data

This intervention maps to 26 entities in the Healos knowledge graph.

20

Conditions

3

Biomarkers

2

Specialists

0

Symptoms

190

Clinical Trials

Data is sourced from SNOMED CT, UMLS, and the Healos clinical knowledge graph. Content sections marked as pending require physician authorship. Consult a healthcare provider before starting any treatment.